DE60306505D1 - Verfahren zur behandlung von brustdrüsenerkrankungen - Google Patents

Verfahren zur behandlung von brustdrüsenerkrankungen

Info

Publication number
DE60306505D1
DE60306505D1 DE60306505T DE60306505T DE60306505D1 DE 60306505 D1 DE60306505 D1 DE 60306505D1 DE 60306505 T DE60306505 T DE 60306505T DE 60306505 T DE60306505 T DE 60306505T DE 60306505 D1 DE60306505 D1 DE 60306505D1
Authority
DE
Germany
Prior art keywords
treatment
breast cancer
cancer diseases
diseases
neuroblastoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60306505T
Other languages
English (en)
Other versions
DE60306505T2 (de
Inventor
F Brin
Stephen Donovan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32867445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60306505(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DE60306505D1 publication Critical patent/DE60306505D1/de
Publication of DE60306505T2 publication Critical patent/DE60306505T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Processing Of Meat And Fish (AREA)
  • Steroid Compounds (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Peptides Or Proteins (AREA)
DE60306505T 2002-02-08 2003-02-04 Verfahren zur behandlung von brustdrüsenerkrankungen Expired - Lifetime DE60306505T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71826 2002-02-08
US10/071,826 US7838007B2 (en) 1999-12-07 2002-02-08 Methods for treating mammary gland disorders
PCT/US2003/003479 WO2004071525A1 (en) 2002-02-08 2003-02-04 Methods for treating mammary gland disorders

Publications (2)

Publication Number Publication Date
DE60306505D1 true DE60306505D1 (de) 2006-08-10
DE60306505T2 DE60306505T2 (de) 2007-01-11

Family

ID=32867445

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60306505T Expired - Lifetime DE60306505T2 (de) 2002-02-08 2003-02-04 Verfahren zur behandlung von brustdrüsenerkrankungen

Country Status (12)

Country Link
US (2) US7838007B2 (de)
EP (3) EP1492561B1 (de)
JP (2) JP4889220B2 (de)
AT (1) ATE331527T1 (de)
AU (1) AU2003225549B2 (de)
BR (1) BR0307496A (de)
CA (1) CA2478902C (de)
DE (1) DE60306505T2 (de)
DK (1) DK1492561T3 (de)
ES (1) ES2264041T3 (de)
PT (1) PT1492561E (de)
WO (1) WO2004071525A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US7838007B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
AU2001270219A1 (en) * 2000-06-28 2002-01-08 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
US7824693B2 (en) 2002-08-19 2010-11-02 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
EP2272340B1 (de) 2002-08-19 2018-03-14 Ira Sanders Botulinumtoxin
US20120114697A1 (en) 2002-08-19 2012-05-10 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US8084041B2 (en) * 2003-01-24 2011-12-27 Albert Einstein College Of Medicine Of Yeshiva University Use of mycrobacterial vaccines in CD4+ or CD8+ lymphocyte-deficient mammals
EP1626711A4 (de) * 2003-05-09 2010-10-06 Univ Pennsylvania Zusammensetzungen und verfahren zur behandlung von krebs
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
WO2006086001A2 (en) * 2004-07-20 2006-08-17 Allergan, Inc. Thermographic assessment of clostridial toxin applications
US20070258900A1 (en) * 2004-07-20 2007-11-08 Joseph Francis Blood Flow Assessment of Clostridial Toxin Applications
US8343929B2 (en) * 2004-09-23 2013-01-01 Toxcure, Inc. Treating neoplasms with neurotoxin
EP2168594B1 (de) * 2004-09-23 2015-04-29 Toxcure, Inc. Behandlung von Neoplasmen mit Neurotoxin
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US8155408B2 (en) * 2008-04-15 2012-04-10 General Electric Company Standardized normal database having anatomical phase information
ES2599033T3 (es) 2008-11-26 2017-01-31 Toxcure, Inc. Tratamiento de neoplasias con neurotoxina
US8629103B2 (en) 2010-12-02 2014-01-14 New York University Treatment of non-proliferative cystic disease of the breast
WO2012097189A1 (en) * 2011-01-13 2012-07-19 Rutgers, The State University Of New Jersey Systems and methods for multi-protocol registration and tissue classification using local morphologic scale (lms)
US9144600B2 (en) 2011-07-14 2015-09-29 Allergan, Inc. Methods for treatment of incontinence associated with sexual activity
EP2649983A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (II)
EP2836193B1 (de) 2012-04-13 2018-01-31 Lubrizol Advanced Materials, Inc. Verbindungen zur hemmung neuronaler exozytose (ii)
EP2649985A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (III)
EP2649984A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose
WO2020047159A1 (en) 2018-08-28 2020-03-05 Ira Sanders Skin therapeutics

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664911A (en) 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5466672A (en) 1992-12-04 1995-11-14 Ophidian Pharmaceuticals, Inc. Therapeutic use of clostridium difficile toxin A
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
CA2312047A1 (en) 1994-05-09 1995-11-16 William J. Binder Method for reduction of headache pain
US5595740A (en) 1994-05-16 1997-01-21 University Of Florida Cloning of non-IgA FC binding forms of the group B streptococcal beta antigens
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
ES2336924T5 (es) * 1997-07-15 2014-04-30 The Regents Of The University Of Colorado Uso de toxina botulínica para el tratamiento de disfunción recalcitrante de evacuación
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
DE19802569A1 (de) 1998-01-23 1999-09-09 Univ Albert Ludwigs Freiburg Toxikologisch aktive Fragmente des lethalen Toxins von Clostridium sordellii und deren Verwendung in Immuntoxinen
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
CN1324246A (zh) 1998-10-27 2001-11-28 梅约医学教育与研究基金会 增加伤口愈合的方法
DE19852981A1 (de) 1998-11-17 2000-05-18 Martin Schmidt Botulinum-Toxine, deren Derivate, Analoge und molekulare Bruchstücke zur topischen epicutanen Anwendung auch in Zusammenwirken mit hautpenetrationsfördernden Substanzen und Maßnahmen in Zubereitungsformen zur Beeinflussung acetylcholinabhängiger Körperfunktionen
DE19856052A1 (de) 1998-12-04 2000-06-08 Deutsches Krebsforsch Konjugat zur Anreicherung in neuronalen Zellen
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
EP1135094B1 (de) 1999-04-16 2009-03-11 Marvin Schwartz Verfahren zur verminderung des haarausfalls und förderung des haarwiederwachstums
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US7838007B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6261572B1 (en) 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
WO2002009743A1 (en) 2000-08-02 2002-02-07 Allergan Sales, Inc. Method for treating a neoplasm
US6831059B2 (en) 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses

Also Published As

Publication number Publication date
AU2003225549B2 (en) 2006-11-16
US20020094339A1 (en) 2002-07-18
US7846456B2 (en) 2010-12-07
JP2006510723A (ja) 2006-03-30
DE60306505T2 (de) 2007-01-11
AU2003225549A1 (en) 2004-09-06
EP1728517A2 (de) 2006-12-06
CA2478902C (en) 2012-05-01
US7838007B2 (en) 2010-11-23
JP2012025775A (ja) 2012-02-09
BR0307496A (pt) 2005-06-28
JP4889220B2 (ja) 2012-03-07
CA2478902A1 (en) 2004-08-26
EP2204183A1 (de) 2010-07-07
US20050260231A1 (en) 2005-11-24
EP1728517A3 (de) 2008-06-25
ATE331527T1 (de) 2006-07-15
WO2004071525A1 (en) 2004-08-26
PT1492561E (pt) 2006-10-31
EP1492561B1 (de) 2006-06-28
DK1492561T3 (da) 2006-09-25
EP1492561A1 (de) 2005-01-05
ES2264041T3 (es) 2006-12-16

Similar Documents

Publication Publication Date Title
DE60306505D1 (de) Verfahren zur behandlung von brustdrüsenerkrankungen
DE602005015687D1 (de) Phospholipid-analoga für die behandlung von krebs
ATE521357T1 (de) Verfahren zur behandlung von hepatitis
DE60329123D1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
ATE374196T1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
ATE493433T1 (de) Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
ATE522229T1 (de) Anti-ngf-antikörper zur behandlung verschiedener erkrankungen
ATE417037T1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE383853T1 (de) Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE602004023721D1 (de) Zusammensetzungen und methoden für die behandlung von herzerkrankungen
ATE399758T1 (de) Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
DE60216457D1 (de) Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten
DE602005027228D1 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
DE602004024871D1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
ATE460168T1 (de) Nicht-radioaktives strontiummittel zur behandlung von krebs

Legal Events

Date Code Title Description
8363 Opposition against the patent